Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05223751 · ClinicalTrials.gov registry record · NA
Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure
A NA study, sponsored by Lancaster General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT05223751 is a NA study that was terminated before completion, run by Lancaster General Hospital. The registered enrollment target is 65 participants.
The verdict
NCT05223751, a NA study, was terminated before completion, sponsored by Lancaster General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a prospective, randomized, controlled clinical trial in which participants with NYHA class II or III and symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) ≤ 45%) will be assigned to one of two treatment groups: standard of care or breathing therapy.
Interventions
- BEHAVIORAL Meo Health Breathing and humming exercises
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2025-09-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05223751
The ClinicalTrials.gov registry entry for NCT05223751 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lancaster General Hospital, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Meo Health Breathing and humming exercises is the first listed.
NCT05223751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05223751 about?
NCT05223751 is a clinical study titled "Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure". This is a prospective, randomized, controlled clinical trial in which participants with NYHA class II or III and symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) ≤ 45%) will be assigned to one of two treatment groups: standard of care or breathing therapy.
What is the current status of trial NCT05223751?
This trial is currently terminated. It is a NA study. The enrollment target is 65 participants. The study started on 2022-02-07. Estimated completion is 2025-09-12.
What interventions are being tested in trial NCT05223751?
The interventions under investigation include: Meo Health Breathing and humming exercises (BEHAVIORAL).
Who is sponsoring clinical trial NCT05223751?
This trial is sponsored by Lancaster General Hospital, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.